how InvestingPro’s Fair Value spotted SELLAS overvaluation before 44% drop

In July 2026, the biotechnology stock SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was experiencing a surge in stock price, having risen 88% in May and 58% in June. Investor insights from InvestingPro's Fair Value analysis had already flagged the stock as significantly overvalued, anticipating a potential downside of 45%. Trading at $14.98 per share on July 5, SELLAS appeared to be trading at an unsustainable premium based on the model's calculations.

Four months later, the stock had plummeted by 44%, falling to $8.37, validating the prescient warning provided by InvestingPro's Fair Value analysis. The healthcare firm, developing novel cancer immunotherapies, was generating zero EBITDA and posting negative earnings of $0.21 per share when the Fair Value models identified the stock as overvalued in early July.

The disconnect between the stock's price and its intrinsic value was striking, with InvestingPro's analysis estimating a Fair Value of $8.20 compared to the prevailing market price of $14.98. The stock's decline continued through the summer and fall, falling 32% in July alone and experiencing volatile swings through October and November, ultimately reaching $8.37—a 44% drop, just one percentage point away from the predicted 45% downside.

Despite recent developments and market fluctuations impacting the stock, SELLAS's fundamentals remain unchanged, with EBITDA still at zero and the same negative earnings profile. The updated Fair Value estimate from InvestingPro stands at $6.00, suggesting the stock may still have further downside potential despite its substantial decline from July levels.

InvestingPro's comprehensive Fair Value methodology, aggregating multiple valuation approaches, provides investors with a clear view of whether a stock is overpriced or undervalued, enabling informed investment decisions.